---
title: "Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284868671.md"
description: "Seaport Therapeutics, Inc. has priced its upsized IPO of 14.16 million shares at $18 each, raising approximately $254.9 million. The shares will trade on the Nasdaq under the ticker \"SPTX\" starting May 1, 2026, with the offering closing on May 4, 2026. Underwriters have a 30-day option to purchase an additional 2.12 million shares, with Goldman Sachs, J.P. Morgan, and others as joint book-running managers."
datetime: "2026-05-01T05:54:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284868671.md)
  - [en](https://longbridge.com/en/news/284868671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284868671.md)
---

# Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each

Add  as your preferred news source on Google

 Add Now

Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range.

The company is expected to raise about $254.9 million in gross proceeds from the offering. It has also granted underwriters a 30-day option to purchase an additional 2.12 million shares.

The shares are set to begin trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker "SPTX", with the offering expected to close on May 4, 2026. Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and Stifel are serving as joint book-running managers for the deal.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIS.US](https://longbridge.com/en/quote/BIS.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain](https://longbridge.com/en/news/287053604.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)
- [Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing](https://longbridge.com/en/news/286818220.md)